ResMed has announced a quarterly dividend of USD 0.066 per share for CDI holders trading on the ASX, payable on December 17, 2026. The distribution covers the three months ended September 30, 2026, and establishes a November 11 ex-date and November 12 record date for Australian shareholders. For investors holding the security through the ASX CDI structure, the payment will be converted to an AUD equivalent amount based on the exchange rate prevailing at the record date, applying the 10:1 ratio between CDIs and NYSE shares.
The dividend is designated as ordinary and unfranked, carrying no franking credits. A 30 percent withholding tax applies to all payments, a standard treatment for distributions from US-listed companies. This tax provision reduces the net cash received by Australian investors unless they qualify for withholding tax relief or reduced rates under bilateral tax treaties. ResMed has scheduled the release of the estimated AUD conversion on November 13, 2026, providing investors with a clear indication of the expected payment amount in Australian dollars prior to the record date cutoff.
For CDI holders, the timing and currency conversion mechanics warrant careful attention. Since ResMed pays dividends in USD, the AUD value ultimately received depends on FX rates at the record date. This currency exposure differentiates CDI investments from equivalent domestic ASX holdings and creates variability in the AUD yield received across periods. The early release of the estimated AUD equivalent allows investors to plan around the conversion at a predictable point, though actual FX movements may create minor variations on settlement.
The quarterly payment pattern reflects ResMed’s US listing cycle and distinguishes it from many ASX dividend stocks, which typically pay semi-annual or annual distributions. Australian investors comparing ResMed’s returns against domestic peers should account for the higher payment frequency balanced against the absence of franking credits and the ongoing withholding tax. For long-term holders, the consistent quarterly rhythm provides regular income, though the unfranked and taxable nature of distributions means each payment is subject to individual tax circumstances.
A rules-based approach to leveraged ETFs
See how our quantitative strategy works and who it suits.
Explore the strategyBecome an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CARInvestors should watch for the confirmed AUD conversion on November 13 and monitor any company commentary on capital allocation or dividend policy in coming weeks. Changes to ResMed’s capital deployment, business growth, or shareholder return framework could signal shifts in future distribution levels. This announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About ResMed Inc (ASX: RMD)
ResMed Inc develops and manufactures medical devices and cloud-based software for diagnosing, treating, and managing respiratory disorders including sleep apnea, chronic obstructive pulmonary disease, and neuromuscular disease. The company supplies flow generators, masks, and accessories globally, with the majority of revenue derived from operations in the Americas. ResMed also pursues digital health initiatives and acquisitions to enhance clinical data offerings for patients, healthcare providers, and payers in out-of-hospital settings.
Become an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CAR